MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
Stefano LuzzagoOttavio de CobelliFrancesco A MistrettaMattia Luca PiccinelliVito LorussoMichele MorelliRoberto BianchiMichele CatellaniGabriele CozziEttore Di TrapaniPaola PricoloSarah AlessiMatteo FerroGiulia MarvasoDeliu-Victor MateiBarbara Alicja Jereczek-FossaGiuseppe PetraliaGennaro MusiPublished in: Prostate cancer and prostatic diseases (2020)
In biopsy naïve setting, a diagnostic pathway including pre-biopsy mpMRI and TB of only PCa suspicious lesions is not associated with higher rates of csPCa during follow-up, relative to a diagnostic pathway of SB. Moreover, patients with negative baseline mpMRI could safely avoid prostate biopsies and could be followed with repeated PSA testing, since only a small proportion of them would harbor csPCa.
Keyphrases
- prostate cancer
- ultrasound guided
- fine needle aspiration
- radical prostatectomy
- end stage renal disease
- newly diagnosed
- ejection fraction
- mycobacterium tuberculosis
- clinical trial
- magnetic resonance imaging
- peritoneal dialysis
- prognostic factors
- study protocol
- randomized controlled trial
- cross sectional
- computed tomography
- contrast enhanced
- open label
- phase ii
- patient reported